I know this is a journey of decisions and sometimes changing one's mind. As to anastrozole, I have mild osteopenia (a manufactured term to sell Fosamax years ago) that estrogen-depletion would surely turn into osteoporosis unless I took meds to hopefully prevent that. The cardiac concern with the aronatase inhibitors is two-fold. A known and frequent side effect is the triggering of high cholesterol, which I already have and cannot reduce with statens. (Not everyone gets this side effect but it's among the most frequent.) The lipid metabolism doesn't necessarily return to pre-anastrozole levels either upon discontinuing the drug. There is some concern also the effect of the drug on arterial endothelial tissue but the data is recent. The Endopat test, which I once had to consider stroke risk as part of a comprehensive coronary health assessment , measures the endothelial rebound rate. I have the genetic marker for heart disease but, quixotically enough, am so far staying out of trouble with low calcium score and good echocardiogram results. But it's always on my mind and I try to reduce risk factors. If I had a high OncotypeDX risk score, I'd have to balance the downsides and 50% rate of arthyria of anastrozole v. statistical odds of BC recurrence differently. I don't envy any of us trying to balance the trade-offs though glad there are choices.